Abiopharma

🔍 Mehta Vimal (Director)

Company: BioXcel Therapeutics, Inc. (BTAI)

Report Date: 2026-01-01

Detailed Transactions and Holdings:

• Acquired 199,032 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 200,783.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.